The global Alzheimer’s therapeutics market was valued $6,123 million in 2021 and expected to reach $13017.93 million by 2031, with a CAGR of 8.1% from 2022 to 2031.
Alzheimer’s disease is a brain disorder, which slowly destroys memory and thinking skills. It involves the part of the brain that controls thought, memory, and language. It is a progressive form of dementia which is a broader term for conditions which negatively affect memory, and behavior. Alzheimer’s disease causes loss of connection between nerve cells in the brain. This damage initially takes place in the parts of the brain and then results in slow decline of memory which includes entorhinal cortex and later it affects in the areas such as cerebral cortex that is responsible for language, social behavior, and reasoning. Alzheimer’s disease also causes decline in the ability to make reasonable decisions and judgments in everyday situations. Increase in age is the greatest known risk factor of the Alzheimer’s disease. Also, researchers believe that genetics may play an important role in developing Alzheimer’s disease.
The global Alzheimer’s therapeutics market is majorly driven by an alarming increase in the prevalence of Alzheimer’s disease, advancement in R&D activities for drug development, and rise in adoption of early diagnosis drive the growth of the market. For instance, in September 2021, according to World Health Organization, it was estimated that approximately 55 million people around the world suffering from Dementia. Dementia results from a variety of diseases and injuries that primarily affect the brain and Alzheimer’s disease is the most common form of dementia. In addition, as per Center for Disease Control and Prevention, in 2020, it was estimated that approximately 5.8 million American’s were living with Alzheimer’s disease and this is projected to reach nearly triple to 14 million by 2060. Thus, increasing number of cases of Alzheimer’s disease is resulting in growing demand for its treatment, which is subsequently driving the growth of the market.
For instance, in June 2021, Eli Lilly and Company has received an FDA approval for donaemab therapy. The donaemab therapy aims to treat a serious condition of Alzheimer’s disease. Thus, increasing number of product launch drives the substantial growth of the market. Moreover, in April 2021, Amneal completed the acquisition of Kashiv Specialty Pharmaceuticals. This acquisition has aim to expand the Amneal’s business and it has gained pipeline of 505(b) 2 branded products and complex generics. Thus, rising number of acquisitions among key players drives the growth of the market.
Increase in investment by players in R&D and presence of robust pipeline candidates foster the market growth. In addition, rise in expenditure on the development of healthcare infrastructure, increase in public awareness about the disease prevention in developing regions, and surge in demand for personalized medicine are expected to create lucrative opportunities for the expansion of the Alzheimer’s therapeutics market.
According to Bright Focus Foundation Alzheimer’s Disease Facts & Figures, in 2021, it was estimated that there were approximately 6.5 million people were suffering from Alzheimer’s disease in the U.S and is projected to reach to 12.7 million by 2050. In addition, as per same source, in 2021, it was estimated that nearly 500,000 new cases of Alzheimer’s disease were diagnosed in the U.S. Thus, increasing number of people suffer from Alzheimer’s disease propels the growth of the market.
Alzheimer’s disease is the most common in Western Europe and least common in Sub-Saharan Africa. African-Americans are about twice as likely to have Alzheimer’s disease. According to Alzheimer’s Drug Discovery Foundation Diagnostics Accelerator, in 2021, has launched four new research investments for the development of digital biomarkers for Alzheimer’s diagnosis. Thus, rising number of investments by private healthcare organizations for the management of Alzheimer’s disease drives the growth of the market. Additionally, the advancement in the ongoing research activities of pharmaceutical companies and their product offering, launching new products, and other business expansion initiatives such as merger and acquisition, collaborations and new investments into other companies are expected to drive the growth of the market.
However, the global Alzheimer’s therapeutics market is anticipated to be hampered by issues such as the high cost of therapeutics. Moreover, increase in awareness among the population for early diagnosis led to the enhancement of the Alzheimer’s therapeutics sector. This encourages many key players to enter emerging markets, thus offering a lucrative growth opportunity in the Alzheimer’s therapeutics market. Moreover, surge in the research and development activities for the development of novel drugs and therapies, increasing older population leads to rise number of Alzheimer’s disease cases drives the growth of the market.
The Alzheimer’s therapeutics market is studied across by drug class, distribution channel, and region. On the basis of drug class, it is categorized into Cholinesterase inhibitors, N-methyl D-Aspartate Receptor Antagonist, and others. By distribution channel it is divided into hospital pharmacy, drug stores & retail pharmacy, and online pharmacy. By region, the Alzheimer’s therapeutics market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Major players operating in the Alzheimer’s therapeutics market are Biogen Inc., Merck & Co. Inc., Novartis AG, Eisai Co. Ltd., H.Lundbeck A/S, Daiichi Sankyo Company Ltd., AbbVie Inc., Teva Pharmaceuticals Industries Ltd., Eli Lilly and Company, and Lupin.
Alzheimer’s disease is a brain disorder, which slowly destroys memory and thinking skills. It involves the part of the brain that controls thought, memory, and language. It is a progressive form of dementia which is a broader term for conditions which negatively affect memory, and behavior. Alzheimer’s disease causes loss of connection between nerve cells in the brain. This damage initially takes place in the parts of the brain and then results in slow decline of memory which includes entorhinal cortex and later it affects in the areas such as cerebral cortex that is responsible for language, social behavior, and reasoning. Alzheimer’s disease also causes decline in the ability to make reasonable decisions and judgments in everyday situations. Increase in age is the greatest known risk factor of the Alzheimer’s disease. Also, researchers believe that genetics may play an important role in developing Alzheimer’s disease.
The global Alzheimer’s therapeutics market is majorly driven by an alarming increase in the prevalence of Alzheimer’s disease, advancement in R&D activities for drug development, and rise in adoption of early diagnosis drive the growth of the market. For instance, in September 2021, according to World Health Organization, it was estimated that approximately 55 million people around the world suffering from Dementia. Dementia results from a variety of diseases and injuries that primarily affect the brain and Alzheimer’s disease is the most common form of dementia. In addition, as per Center for Disease Control and Prevention, in 2020, it was estimated that approximately 5.8 million American’s were living with Alzheimer’s disease and this is projected to reach nearly triple to 14 million by 2060. Thus, increasing number of cases of Alzheimer’s disease is resulting in growing demand for its treatment, which is subsequently driving the growth of the market.
For instance, in June 2021, Eli Lilly and Company has received an FDA approval for donaemab therapy. The donaemab therapy aims to treat a serious condition of Alzheimer’s disease. Thus, increasing number of product launch drives the substantial growth of the market. Moreover, in April 2021, Amneal completed the acquisition of Kashiv Specialty Pharmaceuticals. This acquisition has aim to expand the Amneal’s business and it has gained pipeline of 505(b) 2 branded products and complex generics. Thus, rising number of acquisitions among key players drives the growth of the market.
Increase in investment by players in R&D and presence of robust pipeline candidates foster the market growth. In addition, rise in expenditure on the development of healthcare infrastructure, increase in public awareness about the disease prevention in developing regions, and surge in demand for personalized medicine are expected to create lucrative opportunities for the expansion of the Alzheimer’s therapeutics market.
According to Bright Focus Foundation Alzheimer’s Disease Facts & Figures, in 2021, it was estimated that there were approximately 6.5 million people were suffering from Alzheimer’s disease in the U.S and is projected to reach to 12.7 million by 2050. In addition, as per same source, in 2021, it was estimated that nearly 500,000 new cases of Alzheimer’s disease were diagnosed in the U.S. Thus, increasing number of people suffer from Alzheimer’s disease propels the growth of the market.
Alzheimer’s disease is the most common in Western Europe and least common in Sub-Saharan Africa. African-Americans are about twice as likely to have Alzheimer’s disease. According to Alzheimer’s Drug Discovery Foundation Diagnostics Accelerator, in 2021, has launched four new research investments for the development of digital biomarkers for Alzheimer’s diagnosis. Thus, rising number of investments by private healthcare organizations for the management of Alzheimer’s disease drives the growth of the market. Additionally, the advancement in the ongoing research activities of pharmaceutical companies and their product offering, launching new products, and other business expansion initiatives such as merger and acquisition, collaborations and new investments into other companies are expected to drive the growth of the market.
However, the global Alzheimer’s therapeutics market is anticipated to be hampered by issues such as the high cost of therapeutics. Moreover, increase in awareness among the population for early diagnosis led to the enhancement of the Alzheimer’s therapeutics sector. This encourages many key players to enter emerging markets, thus offering a lucrative growth opportunity in the Alzheimer’s therapeutics market. Moreover, surge in the research and development activities for the development of novel drugs and therapies, increasing older population leads to rise number of Alzheimer’s disease cases drives the growth of the market.
The Alzheimer’s therapeutics market is studied across by drug class, distribution channel, and region. On the basis of drug class, it is categorized into Cholinesterase inhibitors, N-methyl D-Aspartate Receptor Antagonist, and others. By distribution channel it is divided into hospital pharmacy, drug stores & retail pharmacy, and online pharmacy. By region, the Alzheimer’s therapeutics market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Major players operating in the Alzheimer’s therapeutics market are Biogen Inc., Merck & Co. Inc., Novartis AG, Eisai Co. Ltd., H.Lundbeck A/S, Daiichi Sankyo Company Ltd., AbbVie Inc., Teva Pharmaceuticals Industries Ltd., Eli Lilly and Company, and Lupin.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the alzheimer’s therapeutics market analysis from 2021 to 2031 to identify the prevailing alzheimer’s therapeutics market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the alzheimer’s therapeutics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global alzheimer’s therapeutics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Class
- Cholinesterase inhibitors
- N-Methyl-D-Aspartate (NMDA) receptor antagonist
- Others
By Distribution Channel
- Hospital Pharmacy
- Drug Store and Retail Pharmacy
- Online Pharmacy
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest Of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest Of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest Of LAMEA
Key Market Players
- Biogen
- Merck & Co. Inc.
- Novartis AG
- Eisai Co. Ltd.
- H. Lundbeck A/S
- DAIICHI SANKYO COMPANY, LIMITED
- AbbVie Inc.
- Teva Pharmaceuticals Industries Ltd.
- Eli Lilly and Company
- Lupin Ltd
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
CHAPTER 4: ALZHEIMER’S THERAPEUTICS MARKET, BY DRUG CLASS
4.1 Overview
4.1.1 Market size and forecast
4.2 Cholinesterase inhibitors
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 N-Methyl-D-Aspartate (NMDA) receptor antagonist
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Others
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
CHAPTER 5: ALZHEIMER’S THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
5.1 Overview
5.1.1 Market size and forecast
5.2 Hospital Pharmacy
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 DrU.S.ore and Retail Pharmacy
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Online Pharmacy
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: ALZHEIMER’S THERAPEUTICS MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Drug Class
6.2.3 North America Market size and forecast, by Distribution Channel
6.2.4 North America Market size and forecast, by country
6.2.4.1 U.S.
6.2.4.1.1 Market size and forecast, by Drug Class
6.2.4.1.2 Market size and forecast, by Distribution Channel
6.2.4.2 Canada
6.2.4.2.1 Market size and forecast, by Drug Class
6.2.4.2.2 Market size and forecast, by Distribution Channel
6.2.4.3 Mexico
6.2.4.3.1 Market size and forecast, by Drug Class
6.2.4.3.2 Market size and forecast, by Distribution Channel
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Drug Class
6.3.3 Europe Market size and forecast, by Distribution Channel
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Market size and forecast, by Drug Class
6.3.4.1.2 Market size and forecast, by Distribution Channel
6.3.4.2 France
6.3.4.2.1 Market size and forecast, by Drug Class
6.3.4.2.2 Market size and forecast, by Distribution Channel
6.3.4.3 UK
6.3.4.3.1 Market size and forecast, by Drug Class
6.3.4.3.2 Market size and forecast, by Distribution Channel
6.3.4.4 Italy
6.3.4.4.1 Market size and forecast, by Drug Class
6.3.4.4.2 Market size and forecast, by Distribution Channel
6.3.4.5 Spain
6.3.4.5.1 Market size and forecast, by Drug Class
6.3.4.5.2 Market size and forecast, by Distribution Channel
6.3.4.6 Rest of Europe
6.3.4.6.1 Market size and forecast, by Drug Class
6.3.4.6.2 Market size and forecast, by Distribution Channel
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Drug Class
6.4.3 Asia-Pacific Market size and forecast, by Distribution Channel
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 Japan
6.4.4.1.1 Market size and forecast, by Drug Class
6.4.4.1.2 Market size and forecast, by Distribution Channel
6.4.4.2 China
6.4.4.2.1 Market size and forecast, by Drug Class
6.4.4.2.2 Market size and forecast, by Distribution Channel
6.4.4.3 Australia
6.4.4.3.1 Market size and forecast, by Drug Class
6.4.4.3.2 Market size and forecast, by Distribution Channel
6.4.4.4 India
6.4.4.4.1 Market size and forecast, by Drug Class
6.4.4.4.2 Market size and forecast, by Distribution Channel
6.4.4.5 South Korea
6.4.4.5.1 Market size and forecast, by Drug Class
6.4.4.5.2 Market size and forecast, by Distribution Channel
6.4.4.6 Rest of Asia-Pacific
6.4.4.6.1 Market size and forecast, by Drug Class
6.4.4.6.2 Market size and forecast, by Distribution Channel
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Drug Class
6.5.3 LAMEA Market size and forecast, by Distribution Channel
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Brazil
6.5.4.1.1 Market size and forecast, by Drug Class
6.5.4.1.2 Market size and forecast, by Distribution Channel
6.5.4.2 Saudi Arabia
6.5.4.2.1 Market size and forecast, by Drug Class
6.5.4.2.2 Market size and forecast, by Distribution Channel
6.5.4.3 South Africa
6.5.4.3.1 Market size and forecast, by Drug Class
6.5.4.3.2 Market size and forecast, by Distribution Channel
6.5.4.4 Rest of LAMEA
6.5.4.4.1 Market size and forecast, by Drug Class
6.5.4.4.2 Market size and forecast, by Distribution Channel
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 Biogen
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 Merck & Co. Inc.
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 Novartis AG
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 Eisai Co. Ltd.
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 H. Lundbeck A/S
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 DAIICHI SANKYO COMPANY, LIMITED
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 AbbVie Inc.
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Teva Pharmaceuticals Industries Ltd.
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 Eli Lilly and Company
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 Lupin Ltd
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments
List of Tables
Table 1. Global Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 2. Alzheimer's Therapeutics Market, for Cholinesterase Inhibitors, by Region, 2021-2031 ($Million)
Table 3. Alzheimer's Therapeutics Market for Cholinesterase Inhibitors, by Country, 2021-2031 ($Million)
Table 4. Alzheimer's Therapeutics Market, for N-Methyl-D-Aspartate (Nmda) Receptor Antagonist, by Region, 2021-2031 ($Million)
Table 5. Alzheimer's Therapeutics Market for N-Methyl-D-Aspartate (Nmda) Receptor Antagonist, by Country, 2021-2031 ($Million)
Table 6. Alzheimer's Therapeutics Market, for Others, by Region, 2021-2031 ($Million)
Table 7. Alzheimer's Therapeutics Market for Others, by Country, 2021-2031 ($Million)
Table 8. Global Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 9. Alzheimer's Therapeutics Market, for Hospital Pharmacy, by Region, 2021-2031 ($Million)
Table 10. Alzheimer's Therapeutics Market for Hospital Pharmacy, by Country, 2021-2031 ($Million)
Table 11. Alzheimer's Therapeutics Market, for DrU.S.ore and Retail Pharmacy, by Region, 2021-2031 ($Million)
Table 12. Alzheimer's Therapeutics Market for DrU.S.ore and Retail Pharmacy, by Country, 2021-2031 ($Million)
Table 13. Alzheimer's Therapeutics Market, for Online Pharmacy, by Region, 2021-2031 ($Million)
Table 14. Alzheimer's Therapeutics Market for Online Pharmacy, by Country, 2021-2031 ($Million)
Table 15. Alzheimer's Therapeutics Market, by Region, 2021-2031 ($Million)
Table 16. North America Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 17. North America Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 18. North America Alzheimer's Therapeutics Market, by Country, 2021-2031 ($Million)
Table 19. U.S. Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 20. U.S. Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 21. Canada Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 22. Canada Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 23. Mexico Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 24. Mexico Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 25. Europe Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 26. Europe Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 27. Europe Alzheimer's Therapeutics Market, by Country, 2021-2031 ($Million)
Table 28. Germany Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 29. Germany Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 30. France Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 31. France Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 32. UK Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 33. UK Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 34. Italy Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 35. Italy Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 36. Spain Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 37. Spain Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 38. Rest of Europe Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 39. Rest of Europe Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 40. Asia-Pacific Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 41. Asia-Pacific Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 42. Asia-Pacific Alzheimer's Therapeutics Market, by Country, 2021-2031 ($Million)
Table 43. Japan Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 44. Japan Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 45. China Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 46. China Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 47. Australia Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 48. Australia Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 49. India Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 50. India Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 51. South Korea Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 52. South Korea Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 53. Rest of Asia-Pacific Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 54. Rest of Asia-Pacific Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 55. LAMEA Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 56. LAMEA Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 57. LAMEA Alzheimer's Therapeutics Market, by Country, 2021-2031 ($Million)
Table 58. Brazil Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 59. Brazil Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 60. Saudi Arabia Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 61. Saudi Arabia Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 62. South Africa Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 63. South Africa Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 64. Rest of LAMEA Alzheimer's Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 65. Rest of LAMEA Alzheimer's Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 66. Biogen: Company Snapshot
Table 67. Biogen: Operating Segments
Table 68. Biogen: Product Portfolio
Table 69. Biogen: Net Sales
Table 70. Biogen: Key Strategies
Table 71. Merck & Co. Inc.: Company Snapshot
Table 72. Merck & Co. Inc.: Operating Segments
Table 73. Merck & Co. Inc.: Product Portfolio
Table 74. Merck & Co. Inc.: Net Sales
Table 75. Merck & Co. Inc.: Key Strategies
Table 76. Novartis AG: Company Snapshot
Table 77. Novartis AG: Operating Segments
Table 78. Novartis AG: Product Portfolio
Table 79. Novartis AG: Net Sales
Table 80. Novartis AG: Key Strategies
Table 81. Eisai Co. Ltd.: Company Snapshot
Table 82. Eisai Co. Ltd.: Operating Segments
Table 83. Eisai Co. Ltd.: Product Portfolio
Table 84. Eisai Co. Ltd.: Net Sales
Table 85. Eisai Co. Ltd.: Key Strategies
Table 86. H. Lundbeck A/S: Company Snapshot
Table 87. H. Lundbeck A/S: Operating Segments
Table 88. H. Lundbeck A/S: Product Portfolio
Table 89. H. Lundbeck A/S: Net Sales
Table 90. H. Lundbeck A/S: Key Strategies
Table 91. Daiichi Sankyo Company, Limited: Company Snapshot
Table 92. Daiichi Sankyo Company, Limited: Operating Segments
Table 93. Daiichi Sankyo Company, Limited: Product Portfolio
Table 94. Daiichi Sankyo Company, Limited: Net Sales
Table 95. Daiichi Sankyo Company, Limited: Key Strategies
Table 96. Abbvie Inc.: Company Snapshot
Table 97. Abbvie Inc.: Operating Segments
Table 98. Abbvie Inc.: Product Portfolio
Table 99. Abbvie Inc.: Net Sales
Table 100. Abbvie Inc.: Key Strategies
Table 101. Teva Pharmaceuticals Industries Ltd.: Company Snapshot
Table 102. Teva Pharmaceuticals Industries Ltd.: Operating Segments
Table 103. Teva Pharmaceuticals Industries Ltd.: Product Portfolio
Table 104. Teva Pharmaceuticals Industries Ltd.: Net Sales
Table 105. Teva Pharmaceuticals Industries Ltd.: Key Strategies
Table 106. Eli Lilly and Company: Company Snapshot
Table 107. Eli Lilly and Company: Operating Segments
Table 108. Eli Lilly and Company: Product Portfolio
Table 109. Eli Lilly and Company: Net Sales
Table 110. Eli Lilly and Company: Key Strategies
Table 111. Lupin Ltd.: Company Snapshot
Table 112. Lupin Ltd.: Operating Segments
Table 113. Lupin Ltd.: Product Portfolio
Table 114. Lupin Ltd.: Net Sales
Table 115. Lupin Ltd.: Key Strategies
List of Figures
Figure 1. Alzheimer’S Therapeutics Market Segmentation
Figure 2. Alzheimer’S Therapeutics Market, 2021-2031
Figure 3. Alzheimer’S Therapeutics Market, 2021-2031
Figure 4. Top Investment Pockets, by Region
Figure 5. Porter Five-1
Figure 6. Porter Five-2
Figure 7. Porter Five-3
Figure 8. Porter Five-4
Figure 9. Porter Five-5
Figure 10. Top Player Positioning
Figure 11. Alzheimer’S Therapeutics Mark.:Drivers, Restraints and Opportunities
Figure 12. Alzheimer’S Therapeutics Market, By Drug Class, 2021(%)
Figure 13. Comparative Share Analysis of Cholinesterase Inhibitors Alzheimer’S Therapeutics Market, 2021-2031(%)
Figure 14. Comparative Share Analysis of N-Methyl-D-Aspartate (Nmda) Receptor Antagonist Alzheimer’S Therapeutics Market, 2021-2031(%)
Figure 15. Comparative Share Analysis of Others Alzheimer’S Therapeutics Market, 2021-2031(%)
Figure 16. Alzheimer’S Therapeutics Market, By Distribution Channel, 2021(%)
Figure 17. Comparative Share Analysis of Hospital Pharmacy Alzheimer’S Therapeutics Market, 2021-2031(%)
Figure 18. Comparative Share Analysis of Drug Store and Retail Pharmacy Alzheimer’S Therapeutics Market, 2021-2031(%)
Figure 19. Comparative Share Analysis of Online Pharmacy Alzheimer’S Therapeutics Market, 2021-2031(%)
Figure 20. Alzheimer’S Therapeutics Market by Region, 2021
Figure 21. U.S. Alzheimer’S Therapeutics Market, 2021-2031($Million)
Figure 22. Canada Alzheimer’S Therapeutics Market, 2021-2031($Million)
Figure 23. Mexico Alzheimer’S Therapeutics Market, 2021-2031($Million)
Figure 24. Germany Alzheimer’S Therapeutics Market, 2021-2031($Million)
Figure 25. France Alzheimer’S Therapeutics Market, 2021-2031($Million)
Figure 26. Uk Alzheimer’S Therapeutics Market, 2021-2031($Million)
Figure 27. Italy Alzheimer’S Therapeutics Market, 2021-2031($Million)
Figure 28. Spain Alzheimer’S Therapeutics Market, 2021-2031($Million)
Figure 29. Rest of Europe Alzheimer’S Therapeutics Market, 2021-2031($Million)
Figure 30. Japan Alzheimer’S Therapeutics Market, 2021-2031($Million)
Figure 31. China Alzheimer’S Therapeutics Market, 2021-2031($Million)
Figure 32. Australia Alzheimer’S Therapeutics Market, 2021-2031($Million)
Figure 33. India Alzheimer’S Therapeutics Market, 2021-2031($Million)
Figure 34. South Korea Alzheimer’S Therapeutics Market, 2021-2031($Million)
Figure 35. Rest of Asia-Pacific Alzheimer’S Therapeutics Market, 2021-2031($Million)
Figure 36. Brazil Alzheimer’S Therapeutics Market, 2021-2031($Million)
Figure 37. Saudi Arabia Alzheimer’S Therapeutics Market, 2021-2031($Million)
Figure 38. South Africa Alzheimer’S Therapeutics Market, 2021-2031($Million)
Figure 39. Rest of LAMEA Alzheimer’S Therapeutics Market, 2021-2031($Million)
Figure 40. Top Winning Strategies, by Year
Figure 41. Top Winning Strategies, by Development
Figure 42. Top Winning Strategies, by Company
Figure 43. Product Mapping of Top 10 Players
Figure 44. Competitive Dashboard
Figure 45. Competitive Heatmap of Top 10 Key Players
Figure 46. Bioge.: Net Sales, ($Million)
Figure 47. Merck & Co. Inc.: Net Sales, ($Million)
Figure 48. Novartis A.: Net Sales, ($Million)
Figure 49. Eisai Co. Ltd.: Net Sales, ($Million)
Figure 50. H. Lundbeck A/.: Net Sales, ($Million)
Figure 51. Daiichi Sankyo Company, Limite.: Net Sales, ($Million)
Figure 52. Abbvie Inc.: Net Sales, ($Million)
Figure 53. Teva Pharmaceuticals Industries Ltd.: Net Sales, ($Million)
Figure 54. Eli Lilly and Compan.: Net Sales, ($Million)
Figure 55. Lupin Lt.: Net Sales, ($Million)
Executive Summary
According to the report, “Alzheimer’s Therapeutics Market," the Alzheimer’s therapeutics market size was valued at $6.1 billion in 2021, and is estimated to reach $13 billion by 2031, growing at a CAGR of 8.1% from 2022 to 2031.Alzheimer’s disease is a type of brain disease. The neurons damaged in the parts of the brain can be responsible for memory, language, and thinking. As time passes, more neurons are damaged and more areas of the brain are affected. In the mild stage of Alzheimer’s disease, most people are able to function independently in many areas but are likely to require assistance with some activities to maximize independence. In moderate stage, individuals experience more problems with memory and languages, and are more likely to become confused. Moreover, some individuals lose their ability to communicate verbally.
The major factor that drives the growth of the Alzheimer’s therapeutics market is the increase in life expectancy, rise in ageing population, and changes in lifestyle. In addition, the growth is associated with rapid improvement in medical infrastructure, increase in scientific studies associated with the treatment and monitoring of Alzheimer's disease, as well as significant government and private sector funding in the Alzheimer's research is driving the market growth. According to the National Library of Medicine, it is projected that the cost of Alzheimer’s disease therapeutics is set to increase $2 trillion by 2030. Thus, rise in cost of drugs for the treatment of Alzheimer’s disease drives the growth of the market. Furthermore, according to The Lancet Commission 2020 report on dementia prevention, intervention, and care recommends to address the physical and mental health care, and, management of neuropsychiatric symptoms. Thus, rise in initiatives taken by private organizations for the management of Alzheimer’s disease drives the growth of the market.
Moreover, increase in prevalence of genetic disease significantly contributes toward the growth of Alzheimer's therapeutics industry, owing to rise in number of drug approvals acts a key driving force of the global market. Furthermore, governments of many countries are taking multiple initiatives to develop various awareness programs, which is one of the major ongoing Alzheimer's therapeutics market trends. For instance, in April 2021, Amneal has acquired Kashiv Specialty Pharmaceuticals, this acquisition aim to gained the pipeline of 505 (b) 2 branded products and complex generics for the management of neurological diseases such as Alzheimer’s disease. Thus, rising number of product approval drives the growth of the Alzheimer’s therapeutics market.
According to Alzheimer’s Association, in 2022, it is estimated that there are 6.5 million cases of Alzheimer’s disease with aged 65 and older in the U.S. The percentage of individuals suffer from Alzheimer’s disease increases with age: 5:0% of people age between 65 and 74, 13.1% of people age 75 to 84, and 33.2% of people with the age 85 and older. In addition, as per the same source, the number of people with age 65 and older with Alzheimer’s disease is projected to reach 13.8 million, barring the development of medical care breakthrough to prevent or cure Alzheimer’s disease. Thus, rise in older population in the world led to increase in prevalence of Alzheimer’s disease significantly augment the growth of the market.
In addition, according to Center for Disease Control and Prevention 2019, it was estimated that approximately 121,499 people died from Alzheimer’s disease. Moreover, as per Chicago Health and Aging Project study in 2020, it was estimated that 700,000 people with age 65 and older died from Alzheimer’s disease. Thus, rise in incidences of individuals suffering from Alzheimer’s disease is anticipated to boost the growth of the market.
Moreover, development of pharmaceutical industries and improvement in healthcare spending are anticipated to drive the growth of the Alzheimer’s therapeutics market. Thus, presence of innovative product lines fuels the growth of the Alzheimer’s therapeutics market.However, patent expiry of Alzheimer’s therapeutics are expected to restrain the market growth. Conversely, huge market potential in the emerging markets, such as China and India, and increase in healthcare expenditure in developing countries are expected to provide lucrative opportunities to the market players.
The Alzheimer's therapeutics market size is studied across by drug class, distribution channel, and region. By drug class the market it is categorized into Cholinesterase inhibitors, N-methyl D-Aspartate Receptor Antagonist, and others. By distribution channel it is divided into hospital pharmacy, drug stores & retail pharmacy, and online pharmacy. By region, the Alzheimer's therapeutics industry is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
By drug class, the market is segmented into Cholinesterase inhibitors, N-methyl D-Aspartate Receptor Antagonist, and others. The cholinesterase inhibitors segment generated the highest revenue in 2021 and the others segment shows highest CAGR during the analysis period.
By distribution channel, the market is categorized into hospital pharmacy, drug stores & retail pharmacy, and online pharmacy. Drug store & retail pharmacy is the highest revenue-generating segment in the Alzheimer’s therapeutics market, during the analysis period. However, online pharmacy is recorded to be the fastest growing segment and tend to flourish during the forecast period.
By region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest Alzheimer's therapeutics market share in 2021, and is expected to remain dominant throughout the forecast period, owing to increase awareness among the consumers for the adoption of Alzheimer’s therapeutics, and heavy investment in the research and development field is anticipated to drive the growth of the market. However, with rise in government initiatives for the management of Alzheimer’s disease in Asia-Pacific is anticipated to be the fastest growing during the forecast period.
Key Findings of the Study
- According to Alzheimer's therapeutics market analysis, among drugs class, the cholinesterase segment held largest market share in 2021
- By distribution channel, the drug store & retail pharmacy segment held largest market share in 2021, and is expected to remain dominant throughout the forecast period.
- By region, North America accounted for largest share of the global Alzheimer’s therapeutics market in 2021. Asia-Pacific is expected to grow at the highest CAGR during the Alzheimer's therapeutics market forecast
Companies Mentioned
- Biogen
- Merck & Co. Inc.
- Novartis AG
- Eisai Co. Ltd.
- H. Lundbeck A/S
- DAIICHI SANKYO COMPANY, LIMITED
- AbbVie Inc.
- Teva Pharmaceuticals Industries Ltd.
- Eli Lilly and Company
- Lupin Ltd
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 172 |
| Published | September 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 6123 million |
| Forecasted Market Value ( USD | $ 13017.93 million |
| Compound Annual Growth Rate | 7.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
![Global Alzheimer's Therapeutics Market by Drug Class (Cholinesterase Inhibitors, NMDA [N-methyl-D-aspartate] Receptor Antagonist), Type (Medication, NMDA Receptor Antagonist), Distribution - Forecast 2024-2030 - Product Image](http://www.researchandmarkets.com/product_images/11393/11393578_60px_jpg/global_alzheimers_therapeutics_market.jpg)
